Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | POLRMT | O00411 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 7/20 | 0.34 |
| ▸ | IMPDH1 | P20839 | 5/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.33 |
| ▸ | NADK | O95544 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22646509 | 0.97 | CA12 (0.39) | CA12CA1CA2CA9POLRMT | |
| SCHEMBL18636617 | 0.87 | CA12 (0.40) | CA12CA1CA2CA9POLRMT | |
| SCHEMBL19779075 | 0.83 | POLRMT (0.46) | CA12CA1CA2CA9POLRMT | |
| SCHEMBL26251486 | 0.82 | CA12 (0.37) | CA12CA1CA2CA9POLRMT | |
| SCHEMBL13667664 | 0.82 | CA12 (0.37) | CA12CA1CA2CA9POLRMT | |
| SCHEMBL18666929 | 0.81 | CA12 (0.38) | CA12CA1CA2CA9POLRMT | |
| SCHEMBL26254436 | 0.81 | CA12 (0.36) | CA12CA1CA2CA9POLRMT | |
| SCHEMBL18636618 | 0.81 | CA12 (0.36) | CA12CA1CA2CA9POLRMT | |
| SCHEMBL16708563 | 0.80 | POLRMT (0.44) | CA12CA1CA2CA9POLRMT | |
| SCHEMBL16710702 | 0.80 | POLRMT (0.40) | CA12CA1CA2CA9POLRMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2017-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10251904-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | CA12 2132/4885CA1 2531/4885CA2 3752/4885 |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | ACE2, ACE, PNP | CA12 770/4885CA1 3405/4885CA2 1690/4885 |
| US-20170071964-A1 | METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS | ACE, PNP, ACE2 | CA12 2132/4885CA1 2531/4885CA2 3752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.